Investigating hexokinase 2's role in cancer therapy
Hexokinase 2 and cancer therapy
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-10875294
This study is looking at a special protein called HK2 that cancer cells use to process sugar differently than normal cells, and it aims to find new ways to stop cancer from growing by understanding how HK2 affects both the cancer cells and their surroundings.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-10875294 on ClinicalTrials.gov |
What this research studies
This research focuses on the unique metabolic characteristics of cancer cells, particularly their high glucose metabolism driven by hexokinase 2 (HK2). Unlike normal cells that primarily express hexokinase 1, cancer cells express elevated levels of HK2, making it a potential target for therapy. The study aims to explore novel functions of HK2 beyond its role in glucose metabolism, including its impact on protein stability and the tumor microenvironment. By understanding these mechanisms, the research seeks to develop new strategies for inhibiting cancer growth and improving treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with various types of cancer, including breast, lung, liver, and prostate cancers.
Not a fit: Patients with cancers that do not express hexokinase 2 or those with early-stage cancers that are not yet metabolically altered may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative cancer therapies that specifically target the metabolic pathways of cancer cells, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting hexokinase 2 in animal models, indicating potential for success in human applications.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAY, NISSIM — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: HAY, NISSIM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.